NeoGenomics Inc (FRA:NG9)
€ 12 0 (0%) Market Cap: 1.57 Bil Enterprise Value: 1.78 Bil PE Ratio: 0 PB Ratio: 1.82 GF Score: 70/100

Neogenomics Inc at Morgan Stanley Healthcare Conference Transcript

Sep 10, 2019 / 01:10PM GMT
Release Date Price: €20.57 (-8.17%)
Unidentified Analyst

Okay. Great. Well, thanks for joining us, day 2 of the Morgan Stanley Global Healthcare Conference. Excited to have with us today NeoGenomics. Maybe just to start, please note that all-important disclosures, including personal holding disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at www.morganstanley.com/researchdisclosures.

So with that out of the way, pleased to have with me today Doug VanOort, Chairman, Chief Executive Officer of NeoGenomics; as well as Bill Bonello, Chief Strategy Officer and Corporate Development Officer. Thanks for joining us.

Douglas M. VanOort
NeoGenomics, Inc. - Chairman & CEO

Thanks, [Matt].

Questions & Answers

Unidentified Analyst

Excited to have NEO here. And maybe just, Doug, do you want to take a second off the top to have you sort of level set NeoGenomics for folks. I know you're focused on being the most comprehensive,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot